SCHEMBL5536084

SCHEMBL5536084

Cc1ccc(CNC(=O)c2nc3n(c(=O)c2O)CCS3)cc1C

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.48
GAA P10253 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
CYP2C19 P33261 2/20 0.47
CYP1A2 P05177 1/20 0.47
HTT P42858 3/20 0.44
SMN1; SMN2 Q16637 5/20 0.42
RAB9A P51151 5/20 0.42
NPC1 O15118 4/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 2/20 0.40
KCNH2 Q12809 1/20 0.40
LMNA P02545 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TAAR1 Q96RJ0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5533074 0.91 GAA (0.50) TSHRGAANPSR1CYP2C19CYP1A2
SCHEMBL5539137 0.86 GAA (0.48) TSHRGAANPSR1CYP2C19CYP1A2
SCHEMBL5533078 0.84 GAA (0.67) TSHRGAANPSR1CYP2C19CYP1A2
SCHEMBL12777981 0.84 CYP2C19 (0.67) TSHRGAANPSR1CYP2C19CYP1A2
SCHEMBL5538434 0.80 KCNH2 (0.40) SMN1; SMN2RAB9ANPC1ALDH1A1KMT2A
SCHEMBL5536861 0.78 KCNH2 (0.41) TSHRGAASMN1; SMN2RAB9ANPC1
SCHEMBL5534183 0.78 NPC1 (0.40) TSHRRAB9ANPC1KMT2AMAPT
SCHEMBL3842530 0.77 KCNH2 (0.42) TSHRGAASMN1; SMN2NPC1ALDH1A1
SCHEMBL13917333 0.77 KCNH2 (0.46) SMN1; SMN2RAB9ANPC1ALDH1A1KMT2A
SCHEMBL13917364 0.77 NPC1 (0.39) TSHRSMN1; SMN2RAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7192948-B2 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-20 US claimed
EP-1753767-A1 BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS Bristol-Myers Squibb Company (US) 2007-02-21 EP claimed
WO-2005118589-A1 BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-12-15 WO claimed
US-20050267132-A1 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-12-01 US claimed
US-7192948-B2 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-20 US disclosed
US-7192948-B2 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-20 US disclosed
US-7192948-B2 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-20 US disclosed
US-20050267132-A1 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267132-A1 Bicyclic heterocycles as HIV integrase inhibitors CCNI, TOP1, APOBEC3C TSHR 4844/4885GAA 1313/4885NPSR1 4500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.